Payment overview · 2025
General Payments
$1,084.70
58 reported records · 18 companies
Healthcare provider profile · identity verified
Michael Sperling, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LITTLE RIVER, SC · NPI 1326579392
Verified facts
What the public records show
CMS Open Payments records show Michael Sperling, M.D. received $1,084.70 in general payments during 2025 across 58 reported records.
Amgen Inc. accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $218.26 | 20.1% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $164.24 | 15.1% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.43 | 9.9% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $89.97 | 8.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.13 | 7.0% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.16 | 6.3% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $66.88 | 6.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.76 | 5.8% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.51 | 4.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.32 | 3.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.16 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.77 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.95 | 1.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.91 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.82 | 1.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.38 | 1.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.33 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.72 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,084.70 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $218.26 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $129.05 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $90.93 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $89.97 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.28 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $66.88 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $63.97 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.76 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $48.51 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $46.59 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $42.72 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.19 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.32 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 134 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 163 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
209 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
59 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1147 | 339 |
| Amlodipine Besylate | Amlodipine Besylate | 734 | 214 |
| Levothyroxine Sodium | Levothyroxine Sodium | 700 | 183 |
| Losartan Potassium | Losartan Potassium | 533 | 151 |
| Omeprazole | Omeprazole | 520 | 157 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 458 | 131 |
| Lisinopril | Lisinopril | 426 | 122 |
| Metformin Hcl | Metformin Hcl | 420 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 90 |
| Simvastatin | Simvastatin | 287 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 255 | 75 |
| Gabapentin | Gabapentin | 250 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 82 |
| Pravastatin Sodium | Pravastatin Sodium | 224 | 65 |
| Furosemide | Furosemide | 221 | 69 |
| Trazodone Hcl | Trazodone Hcl | 221 | 72 |
| Mounjaro | Tirzepatide | 209 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 195 | 168 |
| Prednisone | Prednisone | 177 | 127 |
| Ezetimibe | Ezetimibe | 171 | 58 |
| Citalopram Hbr | Citalopram Hydrobromide | 167 | 52 |
| Meloxicam | Meloxicam | 165 | 64 |
| Ozempic | Semaglutide | 163 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 67 |
| Sertraline Hcl | Sertraline Hcl | 155 | 47 |
| Montelukast Sodium | Montelukast Sodium | 150 | 52 |
| Tramadol Hcl | Tramadol Hcl | 149 | 48 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 147 | 43 |
| Pioglitazone Hcl | Pioglitazone Hcl | 143 | 44 |
| Allopurinol | Allopurinol | 141 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 44 |
| Januvia | Sitagliptin Phosphate | 136 | 35 |
| Eliquis | Apixaban | 134 | 33 |
| Alprazolam | Alprazolam | 130 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 113 | 37 |
| Alendronate Sodium | Alendronate Sodium | 112 | 39 |
| Valsartan | Valsartan | 109 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 32 |
| Finasteride | Finasteride | 108 | 31 |
| Clonazepam | Clonazepam | 106 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 46 |
| Carvedilol | Carvedilol | 105 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 102 | 93 |
| Famotidine | Famotidine | 101 | 37 |
| Glipizide | Glipizide | 100 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 27 |
| Levofloxacin | Levofloxacin | 96 | 72 |
| Azithromycin | Azithromycin | 94 | 84 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 47 |
| Lorazepam | Lorazepam | 82 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 12 |
| Atenolol | Atenolol | 80 | 22 |
| Potassium Chloride | Potassium Chloride | 76 | 25 |
| Donepezil Hcl | Donepezil Hcl | 73 | 26 |
| Repatha Sureclick | Evolocumab | 71 | 15 |
| Ibuprofen | Ibuprofen | 70 | 42 |
| Metformin Hcl Er | Metformin Hcl | 70 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 23 |
| Chlorthalidone | Chlorthalidone | 63 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 50 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | 21 |
| Glipizide Er | Glipizide | 62 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 58 |
| Synthroid | Levothyroxine Sodium | 61 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 59 | 56 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 15 |
| Celecoxib | Celecoxib | 54 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 28 |
| Temazepam | Temazepam | 53 | 13 |
| Estradiol | Estradiol | 52 | 12 |
| Clonidine Hcl | Clonidine Hcl | 51 | 16 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 48 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Fenofibrate | Fenofibrate | 45 | 15 |
| Spironolactone | Spironolactone | 44 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 15 |
| Fluconazole | Fluconazole | 43 | 33 |
| Jardiance | Empagliflozin | 41 | 12 |
| Pregabalin | Pregabalin | 40 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 11 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 28 |
| Lovastatin | Lovastatin | 37 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 21 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 11 |
| Acyclovir | Acyclovir | 31 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 11 |
| Jantoven | Warfarin Sodium | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 11 |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 18 |
| Meclizine Hcl | Meclizine Hcl | 28 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Diazepam | Diazepam | 23 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Praluent Pen | Alirocumab | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 11 |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | 11 |
| Sucralfate | Sucralfate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,084.70 · 58 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, JARDIANCE, Kerendia, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, XIFAXAN | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error